Fouad Namouni's most recent trade in Vor Biopharma Inc was a trade of 30,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vor Biopharma Inc | Fouad Namouni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Fouad Namouni | PRESIDENT, R & D | Sale of securities on an exchange or to another person at price $ 88.80 per share. | 05 Mar 2025 | 6,489 | 75,781 (0%) | 0% | 88.8 | 576,223 | Common Stock |
| Blueprint Medicines Corp | Fouad Namouni | PRESIDENT, R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Fouad Namouni | PRESIDENT, R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 13,200 | 82,270 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Fouad Namouni | PRESIDENT, R & D | Sale of securities on an exchange or to another person at price $ 89.32 per share. | 03 Oct 2024 | 3,633 | 69,070 (0%) | 0% | 89.3 | 324,500 | Common Stock |
| Vor Biopharma Inc | Fouad Namouni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Vor Biopharma Inc | Fouad Namouni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Blueprint Medicines Corp | Fouad Namouni | PRESIDENT, R & D | Sale of securities on an exchange or to another person at price $ 90.69 per share. | 07 Mar 2024 | 4,377 | 72,703 (0%) | 0% | 90.7 | 396,950 | Common Stock |
| Blueprint Medicines Corp | Fouad Namouni | PRESIDENT, R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Fouad Namouni | PRESIDENT, R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 15,000 | 77,080 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Fouad Namouni | PRESIDENT, R & D | Sale of securities on an exchange or to another person at price $ 48.06 per share. | 04 Oct 2023 | 3,769 | 62,080 (0%) | 0% | 48.1 | 181,138 | Common Stock |
| Blueprint Medicines Corp | Fouad Namouni | PRESIDENT, R & D | Sale of securities on an exchange or to another person at price $ 45.72 per share. | 06 Mar 2023 | 1,885 | 65,912 (0%) | 0% | 45.7 | 86,182 | Common Stock |
| Blueprint Medicines Corp | Fouad Namouni | PRESIDENT, R & D | Sale of securities on an exchange or to another person at price $ 44.37 per share. | 06 Mar 2023 | 63 | 65,849 (0%) | 0% | 44.4 | 2,795 | Common Stock |
| Blueprint Medicines Corp | Fouad Namouni | PRESIDENT, R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Fouad Namouni | PRESIDENT, R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 15,000 | 67,797 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Fouad Namouni | PRESIDENT, R & D | Sale of securities on an exchange or to another person at price $ 67.30 per share. | 04 Oct 2022 | 3,477 | 52,797 (0%) | 0% | 67.3 | 234,002 | Common Stock |
| Blueprint Medicines Corp | Fouad Namouni | PRESIDENT, R & D | Sale of securities on an exchange or to another person at price $ 56.19 per share. | 07 Mar 2022 | 1,047 | 56,274 (0%) | 0% | 56.2 | 58,831 | Common Stock |
| Blueprint Medicines Corp | Fouad Namouni | PRESIDENT, R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Fouad Namouni | PRESIDENT, R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 15,000 | 57,321 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Fouad Namouni | President, R & D | Sale of securities on an exchange or to another person at price $ 98.18 per share. | 05 Oct 2021 | 3,241 | 42,321 (0%) | 0% | 98.2 | 318,201 | Common Stock |
| Aprea Therapeutics Inc | Fouad Namouni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 22,750 | 22,750 | - | - | Stock Option (Right to Buy) | |
| Aprea Therapeutics Inc | Fouad Namouni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 4,610 | 4,610 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Fouad Namouni | President, R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 26,125 | 26,125 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Fouad Namouni | President, R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 13,062 | 45,562 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Fouad Namouni | President, R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Fouad Namouni | President, R & D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 32,500 | 32,500 (0%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Fouad Namouni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2020 | 7,000 | 7,000 | - | - | Stock Option (right to Buy) |